8-K: Supernus Pharmaceuticals Stockholders Approve All Proposals at Annual Meeting

Supernus Pharmaceuticals, Inc. announced that its stockholders approved all proposals at the annual meeting held on June 16, 2025, including the re-election of two Class I directors, the non-binding approval of executive compensation, and the ratification of KPMG LLP as the independent auditor.

Summary

• Supernus Pharmaceuticals, Inc. held its annual meeting of stockholders on June 16, 2025.
• As of the record date, April 22, 2025, there were 55,989,623 shares of common stock outstanding and entitled to vote.
• Stockholders re-elected Carolee Barlow, M.D., Ph.D., and Jack A. Khattar as Class I Directors, each to serve until the 2028 Annual Meeting.
• Carolee Barlow received 46,104,993 votes For and 1,426,932 votes Withheld.
• Jack A. Khattar received 46,511,003 votes For and 1,020,922 votes Withheld.
• Stockholders approved, on a non-binding basis, the compensation paid to named executive officers with 45,796,936 votes For, 1,701,777 votes Against, and 33,212 Abstentions.
• The appointment of KPMG LLP as the company's independent public accounting firm for the fiscal year ending December 31, 2025, was ratified with 49,230,498 votes For, 310,868 votes Against, and 15,424 Abstentions.

Sentiment

Score: 7

Explanation: The sentiment is positive as all proposals were approved by stockholders, indicating stability and alignment between shareholders and management. There are no negative or concerning details presented in the filing.

Positives

• All three proposals presented at the annual meeting were approved by stockholders, indicating strong shareholder support for the company's governance and management.
• The re-election of two Class I directors ensures continuity in the board's composition.
• The non-binding approval of executive compensation suggests shareholder alignment with the company's compensation practices.
• The ratification of KPMG LLP as the independent auditor provides stability in financial oversight.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding future financial performance or strategic direction.

Industry Context

This 8-K filing details the routine outcomes of an annual stockholder meeting, which is a standard corporate governance event for publicly traded companies. The results reflect typical shareholder engagement and approval of board and management proposals, consistent with general industry practices for maintaining corporate oversight and accountability.

Corporate Governance

Stakeholder Impact

• Shareholders: Their votes were tabulated and all proposals were approved, indicating their alignment with the company's governance and management decisions.
• Management: The non-binding approval of executive compensation and the re-election of directors suggest a vote of confidence from shareholders.

Next Steps

• The re-elected Class I Directors, Carolee Barlow, M.D., Ph.D., and Jack A. Khattar, will serve until the Company's Annual Meeting in 2028.

Key Dates

Keywords

Supernus Pharmaceuticals, SUPN, Annual Meeting, Stockholder Vote, Director Election, Executive Compensation, Auditor Ratification, Corporate Governance, SEC Filing, 8-K